John-Paul Ong
Research Subjects
John-Paul Ong has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jean Borges Bertoldo
Universidade Federal de Santa Catarina
2 shared publications Joshua Zhu
2 shared publications- Daniel Martins
Ctr. for Audio, Acoust. and Vib., Univ. of Technol. Sydney, 15 Broadway Ultimo, Sydney, New South Wales 2007, Australia
1 shared publication - Dona Johns1 shared publication
Jessica Bell
1 shared publication- Montana Dalziel1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
CanProTarget: A Residue-Resolved Platform for Covalent Target Identification and Drug Discovery in Cancer
Dependency maps nominate transcription factors, RNA-binding proteins and scaffolds without conventional binding sites, while cysteine chemoproteomics has mapped tens of thousands of ligandable sites without reference to disease. Covalent campaigns therefore begin from what is tractable rather than from what a cancer requires. Whether a ligandable cysteine matters requires residue-level functional evidence, and no resource holds all three: combined at the gene level, function measured at one cysteine is credited to a ligand bound at another. We developed CanProTarget to establish where covalent chemistry can realistically begin, returning target–cysteine–ligand hypotheses rather than gene lists. Across twenty adult and pediatric cohorts, 63–75% of gene-level candidates lost support under residue matching. Roughly 80% of ligandable sites were untested rather than assayed non-functional, and the tiers keep them distinct. One untested site nominated IGF2BP3–Cys336–CL174 in neuroblastoma; CL174 engaged IGF2BP3, reduced its mRNA binding and, with depletion, identified BRD3 and H3-3A as IGF2BP3 targets.
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCanProTarget: A Residue-Resolved Platform for Covalent Target Identification and Drug Discovery in Cancer
Dependency maps nominate transcription factors, RNA-binding proteins and scaffolds without conventional binding sites, while cysteine chemoproteomics has mapped tens of thousands of ligandable sites without reference to disease. Covalent campaigns therefore begin from what is tractable rather than from what a cancer requires. Whether a ligandable cysteine matters requires residue-level functional evidence, and no resource holds all three: combined at the gene level, function measured at one cysteine is credited to a ligand bound at another. We developed CanProTarget to establish where covalent chemistry can realistically begin, returning target–cysteine–ligand hypotheses rather than gene lists. Across twenty adult and pediatric cohorts, 63–75% of gene-level candidates lost support under residue matching. Roughly 80% of ligandable sites were untested rather than assayed non-functional, and the tiers keep them distinct. One untested site nominated IGF2BP3–Cys336–CL174 in neuroblastoma; CL174 engaged IGF2BP3, reduced its mRNA binding and, with depletion, identified BRD3 and H3-3A as IGF2BP3 targets.
- Open Access
- 25 September 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6)
Chemoproteomics in covalent cancer drug discovery
- 25 September 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6)
Open AccessChemoproteomics in covalent cancer drug discovery